Phase II Open-Label Trial of Erlotinib (Tarceva) and Bevacizumab (Avastin) in Women With Advanced Ovarian Cancer

Trial Profile

Phase II Open-Label Trial of Erlotinib (Tarceva) and Bevacizumab (Avastin) in Women With Advanced Ovarian Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Bevacizumab; Erlotinib
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 02 Jun 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
    • 02 Jun 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
    • 03 Feb 2009 Planned end date changed from 1 Jul 2008 to 1 May 2009, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top